Systematic review of erythropoiesis-stimulating agent dosing algorithms in hemodialysis patients

被引：0
|
作者：
Meaney, Calvin [1 ]
Gaesser, Jamie [2 ]
Robinson, Ben [2 ]
Krzyzanski, Wojciech [2 ]
Panesar, Mandip [3 ]
Rao, Gauri [4 ]
机构：
[1] SUNY Buffalo, Dept Pharm Practice, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
[3] Erie Cty Med Ctr & Labs, Buffalo, NY USA
[4] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Experiential Educ, Chapel Hill, NC USA
来源：
PHARMACOTHERAPY | 2017年 / 37卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
537
引用
收藏
页码：E235 / E236
页数：2
相关论文
共 50 条
  • [31] Use of erythropoiesis-stimulating agents in obese hemodialysis patients Reply
    El-Kannishy, Ghada M.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) : 310 - 311
  • [32] Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review
    Jorien Laermans
    Hans Van Remoortel
    Bert Avau
    Geertruida Bekkering
    Jørgen Georgsen
    Paola Maria Manzini
    Patrick Meybohm
    Yves Ozier
    Emmy De Buck
    Veerle Compernolle
    Philippe Vandekerckhove
    Systematic Reviews, 11
  • [33] Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review
    Laermans, Jorien
    Van Remoortel, Hans
    Avau, Bert
    Bekkering, Geertruida
    Georgsen, Jorgen
    Manzini, Paola Maria
    Meybohm, Patrick
    Ozier, Yves
    De Buck, Emmy
    Compernolle, Veerle
    Vandekerckhove, Philippe
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [34] Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13
    Birnie, Kate
    Caskey, Fergus
    Ben-Shlomo, Yoav
    Sterne, Jonathan A. C.
    Gilg, Julie
    Nitsch, Dorothea
    Tomson, Charles
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (04) : 692 - 698
  • [35] IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS
    Lefebvre, P.
    Lafeuille, M. H.
    Bailey, R.
    Vekeman, F.
    Piech, C. T.
    McKenzie, R. S.
    VALUE IN HEALTH, 2009, 12 (03) : A55 - A55
  • [36] ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
    Lafeuille, M. H.
    Bailey, R. A.
    Laliberte, F.
    Senbetta, M.
    Vekeman, F.
    McKenzie, R. S.
    Dea, K.
    Lefebvre, P.
    VALUE IN HEALTH, 2010, 13 (03) : A81 - A81
  • [37] Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients
    Minutolo, Roberto
    Borzumati, Maurizio
    Sposini, Stefano
    Abaterusso, Cataldo
    Carraro, Gianni
    Santoboni, Alberto
    Mura, Carlo
    Filiberti, Oliviero
    Santoro, Domenico
    Musacchio, Romano
    Imperiali, Patrizio
    Fiorini, Fulvio
    De Nicola, Luca
    Russo, Domenico
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (01) : 170 - 172
  • [38] Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
    Fishbane, Steven
    Hirsch, Jamie S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (03) : 303 - 305
  • [39] THE EFFECT OF DIFFERENT ERYTHROPOIESIS-STIMULATING AGENT TYPE TO THE INCIDENCE OF ARTERIAL HYPERTENSION IN EUVOLEMIC MAINTENANCE HEMODIALYSIS PATIENTS
    Dorcic, G.
    Simunovic, F.
    Racki, S.
    Devcic, B.
    Radic, J.
    Vujicic, B.
    JOURNAL OF HYPERTENSION, 2016, 34 : E358 - E358
  • [40] USE OF PENTOXIFYLLINE IN HEMODIALYSIS PATIENTS WITH ERYTHROPOIESIS-STIMULATING AGENT (ESA) RESISTANCE: A CASE-CONTROL STUDY
    Nuria, Garcia-Fernandez
    Maria Asuncion, Ferrer
    Jose Maria, Mora-Gutierrez
    Carmen, Calderon
    Paloma Leticia, Martin-Moreno
    Francisco Javier, Lavilla
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 141 - 141
12345